Company Filing History:
1 out of 26 
1 out of 61 
Years Active: 2016
Title: The Innovations of Stephan Von Gunten
Introduction
Stephan Von Gunten is a notable inventor based in Bern, Switzerland, recognized for his contributions to therapeutic innovations. With a focus on the activation of CD89 molecules, Von Gunten’s work addresses significant medical challenges, particularly in disorders characterized by elevated neutrophil levels.
Latest Patents
Stephan Von Gunten holds a patent related to the use of CD89 activating molecules for inducing apoptosis in neutrophils. This invention, titled "CD89 activation in therapy," highlights the therapeutic potential of Fc alpha comprising molecules, particularly IgA and anti-CD89 antibodies. The application of this innovation is crucial for treating various conditions, including autoimmune disorders, inflammatory disorders, NETosis, and cystic fibrosis.
Career Highlights
Throughout his career, Von Gunten has been associated with reputed organizations such as CSL Behring AG and the University of Bern. His experience encompasses both academic and practical applications of his research in the pharmaceutical field, contributing significantly to the advancement of therapy methodologies.
Collaborations
In his journey as an inventor, Stephan has collaborated with notable professionals, including Marc Wehrli and Adrian Zürcher. These partnerships have been instrumental in refining his inventions and extending the reach of his innovative contributions to the medical community.
Conclusion
Stephan Von Gunten’s innovative work in CD89 activation represents a significant advancement in therapeutic strategies for managing conditions linked to neutrophil dysregulation. His patent is a testament to the potential of targeted therapy in addressing complex health issues, showcasing the impact of ingenious minds in the realm of medical research and invention.